pipeline drugs

Over 50 drugmakers advance 55+ hemophilia treatments as Novo Nordisk and competitors pursue gene therapies and next-gen factors.

DelveInsight's 2026 report shows robust rheumatoid arthritis pipeline with 75+ players developing 80+ drugs, featuring novel JAK and BTK inhibitors plus cell-based therapies.

Over 65 pharma companies advance 75+ COPD drugs, shifting from traditional bronchodilators to targeted biologics as AstraZeneca's tozorakimab validates new approaches.

Over 45 companies are developing 50+ follicular lymphoma therapies, with major pharma players advancing 5+ late-stage candidates using diverse mechanisms including protein degraders and kinase inhibitors.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

Over 90 pharmaceutical companies are advancing 100+ psoriasis drugs through clinical trials, with major players like Takeda and Alumis posting positive Phase III results.

SLE drug market projected to grow nearly 150% to $5.9B by 2034 on new therapies, but biosimilar competition and pricing pressure could limit upside.

Atopic dermatitis drug market projected to grow from $8.5B (2023) to $21.5B (2033) at 9.8% CAGR, fueled by seven late-stage pipeline therapies.

Global atopic dermatitis market projected to grow from $10.8B in 2023 to $26.2B by 2033, driven by seven late-stage pipeline drugs and expanded treatment options.

Crohn's Disease drug market projected to grow 45% to $13.8B by 2032, driven by eight new therapies with novel mechanisms of action reshaping competition.

Over 30 pharma companies develop 35+ severe asthma drugs with recent approvals validating new mechanisms, signaling major market opportunity and competitive intensity ahead.

Over 120 pharmaceutical companies are developing 140+ drugs for systemic lupus erythematosus, with major players like Roche and Novartis advancing promising new treatment mechanisms.

JPMorgan raises Edgewise Therapeutics price target to $45, citing positive long-term clinical data for EDG-7500 and sevasemten. Stock rises 2.18%.

Over 50 companies compete in the checkpoint inhibitor market with 60+ drug candidates in development. Major consolidation and innovation drive immuno-oncology growth through 2026.